The Cellular, Tissue and Gene Therapies Advisory Committee — formerly called the Biological Response Modifiers Advisory Committee — reviews and evaluates available data relating to the safety, effectiveness, and appropriate use of human cells, human tissues, gene transfer therapies, and xenotransplantation products that are intended for transplantation, implantation, infusion, and transfer in the prevention and treatment of a broad spectrum of human diseases and in the reconstruction, repair or replacement of tissues for various conditions. Members of the committee include authorities knowledgeable in the fields of cellular therapies, tissue transplantation, hematology/oncology, and human tissues and transplantation, among other specialties.
AABB to Host Instagram Takeover During Cord Blood Awareness Month
July 02, 2024
CMS Releases State RFA for CGT Access Model
July 02, 2024
FDA Simplifies Reporting for CAR T-Cell Therapies with REMS Update
July 01, 2024